STOCK TITAN

PMGC Holdings - ELAB STOCK NEWS

Welcome to our dedicated page for PMGC Holdings news (Ticker: elab), a resource for investors and traders seeking the latest updates and insights on PMGC Holdings stock.

PMGC Holdings Inc. (NASDAQ: ELAB) delivers innovative solutions across biopharmaceuticals, medical aesthetics, and strategic investments. This news hub provides investors with centralized access to all corporate announcements, regulatory updates, and market developments.

Track timely updates on clinical trial progress, partnership agreements, and financial performance. Find press releases covering engineered probiotic therapies for metabolic health, advancements in aesthetic medicine technologies, and strategic moves in fire prevention and energy sectors.

Our curated news collection enables informed decision-making through verified updates on FDA milestones, acquisition activity, and leadership changes. Bookmark this page for ongoing insights into ELAB's diversified growth strategy across healthcare and essential infrastructure markets.

Rhea-AI Summary

Elevai Labs Inc. (NASDAQ: ELAB) announced preliminary positive research data from a study with Dalhousie University, highlighting the potential of its proprietary exosome technology for skin health applications. The study revealed that ELEVAI exosomes™ contain over 800 proteins associated with wound healing, immunomodulation, and skin extracellular matrix remodeling.

Key findings include:

  • ELEVAI exosomes™ demonstrated typical exosome morphology and diameter
  • They were enriched with proteins related to ECM organization, hemostasis, and cellular stress response
  • The protein profile was statistically significant and notably enriched compared to 54 previously published exosome protein datasets
  • Proteins found may help prevent skin thinning, loss of elasticity, and wrinkle formation

Elevai plans to conduct further experiments to expand the research scope and explore broader applications such as bone regeneration, wound healing, and immune regulation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
none
-
Rhea-AI Summary

Elevai Labs Inc. (NASDAQ: ELAB) reported Q2 2024 financial results and provided a business update. Key highlights include:

- Revenue increased 91.3% to $605,529 for Q2 2024 and 165.6% to $1,220,092 for H1 2024 year-over-year.
- Gross margin improved to 72.5% for both Q2 and H1 2024.
- Net loss of $1,412,491 for Q2 and $2,809,741 for H1 2024.
- Launched B2B/B2C Elevai Skincare e-commerce platform.
- Established subsidiaries: Elevai Biosciences Inc. and Elevai Skincare Inc.
- Initiated corporate restructuring to reduce annual operating expenses by an estimated $800,000.
- Received research grant from MITACS Canada.
- Formed Scientific Advisory Board for Elevai Biosciences.

The company continues to focus on growth opportunities and increasing shareholder value through strategic acquisitions and investments in biotech, cosmetic, health, and wellness sectors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.59%
Tags
-
Rhea-AI Summary

Elevai Labs Inc. (NASDAQ: ELAB) has announced the appointment of Orian Shirihai, MD, PhD, to the Scientific Advisory Board of its subsidiary, Elevai Biosciences Inc. Dr. Shirihai, a Professor of Medicine at UCLA and Director of the UCLA Metabolism Research Theme, will support the advancement of EL-22, a first-in-class engineered probiotic approach to address muscle preservation during weight loss treatments.

Dr. Shirihai's expertise in metabolism and obesity research, with over 180 publications and multiple NIH-funded projects, is expected to be valuable in developing EL-22 as a differentiated, oral myostatin approach for obese patients. Elevai Biosciences plans to recruit additional scientific leaders in metabolic health and obesity to join its team.

Elevai Labs Inc. CEO, Graydon Bensler, expressed enthusiasm for the developments at Elevai Biosciences and indicated the company's focus on increasing shareholder value through strategic acquisitions and investments in biotech, cosmetic, health, and wellness spaces.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
management
Rhea-AI Summary

Elevai Labs (NASDAQ: ELAB) has launched the Elevai S-Series™, a new hair and scalp care product line under its subsidiary Elevai Skincare. Unveiled at The Aesthetic Show in Las Vegas on June 28, 2024, the S-Series utilizes a unique dual mechanism combining exosomes and mitochondrial technology. This three-part system, including the Root Renewal System™, is designed to address issues like thinning hair by promoting scalp and hair vitality. The technology integrates Elevai's proprietary PREx™ and Yuva Bioscience's Y100, identified using AI platform MitoGPT. The S-Series aims to provide a scientifically-backed, cost-effective solution for both men and women.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
-
Rhea-AI Summary

Elevai Labs, a leader in the medical aesthetics sector, has announced that its subsidiary, Elevai Skincare, will debut a new product line at The Aesthetic Show 2024, held from June 27-30 at the Wynn Las Vegas.

At Booth #511, Elevai will showcase the latest innovations in stem cell exosome products. CEO and Co-Founder Jordan R. Plews, PhD, will introduce the new product line during a presentation on June 28 at 3:30 PM, joined by guest speaker Keshav Singh, PhD, an acclaimed scientist and inventor of one of the key ingredients in the new products.

This event marks a significant step for Elevai in advancing its product offerings within the medical aesthetics field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
none
-
Rhea-AI Summary

Elevai Labs announced the creation of a new Scientific Advisory Board to support its weight loss program, focusing on the development of EL-22, an engineered probiotic solution aimed at addressing obesity by preserving muscle during weight loss treatments. The board includes experts like Dr. Roger A. Fielding, a leading researcher in skeletal muscle function, and Dr. Eduardo Grunvald, an obesity medicine physician. Elevai CEO Dr. Jordan R. Plews emphasized the board's role in advancing Elevai's vision to address the unmet medical needs of obese patients.

Key members include Dr. Fielding, known for his extensive research on muscle mass decline and nutrition, and Dr. Grunvald, who has vast experience in obesity medicine and weight management. Elevai aims to recruit additional experts in metabolic diseases and obesity to its advisory board.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.16%
Tags
management
Rhea-AI Summary

Elevai Labs announced that its CEO, Dr. Jordan R. Plews, will present at the 2024 Beauty Through Science (BTS) conference in Stockholm on May 30, 2024. BTS is a prestigious annual event attracting over 1,000 participants from around 50 countries, focusing on innovative techniques and technologies in aesthetic medicine. Dr. Plews will discuss the role of exosomes in medical aesthetics during a session titled 'Exosomes: Key Considerations, Regulations and Results,' emphasizing their benefits in promoting natural repair processes. Elevai's participation underscores its commitment to advancing science-driven, data-backed skincare solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
conferences
-
Rhea-AI Summary

Elevai Labs, a leader in medical aesthetics, announced that CEO Dr. Jordan R. Plews will present at the LA-BEST 2024 conference on May 23, 2024. This event, organized by UCLA Technology Development Group, brings together around 1,000 participants to foster biotech innovation. Dr. Plews will discuss Elevai Biosciences' engineered probiotic approach for muscle loss prevention in obesity, particularly focusing on combining this approach with GLP-1 receptor agonists. He will highlight their lead candidate, EL-22, which aims to preserve muscle mass through mucosal immunity and anti-myostatin antibodies. The conference aims to promote biotech partnerships and showcase pioneering research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
-
Rhea-AI Summary

Elevai Labs (NASDAQ: ELAB) reported financial results for Q1 2024, showcasing substantial year-over-year revenue growth and improved gross margins. The company achieved $614,563 in revenue, up 330.3% from $142,820 in Q1 2023, but down 12% from Q4 2023. Gross margin rose to 72.5%, compared to 68.9% in Q1 2023. However, operating expenses increased to $2,129,113, a 125.4% year-over-year rise and a 38% increase from Q4 2023, leading to a total comprehensive loss of $1,396,069. Elevai Labs remains focused on sustainable growth, operational efficiency, and innovation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
Rhea-AI Summary

Elevai Biosciences highlighted preclinical data on their in-licensed asset EL-22 for potential obesity treatment. The data showed improvements in muscle mass and fat reduction in mouse models of Duchenne muscular dystrophy. Elevai plans to submit an IND application in 2025 for clinical trials combining EL-22 with GLP-1 receptor agonists.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.13%
Tags
PMGC Holdings

Nasdaq:ELAB

ELAB Rankings

ELAB Stock Data

1.84M
700.40k
1.15%
0.92%
3.36%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEWPORT BEACH